((自动化翻译由路透提供,请见免责声明 ))
路透1月13日 - 先声药业 周一称,该公司已授予美国制药商艾伯维 在中国以外地区许可其血癌新药候选药物的选择权。
根据协议,艾伯维将向先声药业支付高达10.6亿美元的费用,以及在中国境外销售的特许权使用费。艾伯维将从中国境内的销售中收取特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.